Timothy Myles

Scientific Researcher @Palo Alto Veterans Institute for Research

Palo Alto, CA, US

My current research at PAVIR is understanding how coagulation crosstalk’s with inflammation, wound healing and immunity by defining how thrombin directly cleaves Osteopontin (OPN) to an activated N-terminal domain which exerts new biological functions. Using a mouse strain I designed where OPN is not cleavable by thrombin(OPN-KI), we have shown that in a mouse melanoma model the OPN-KI mice are protected from metastasis and tumour burden. Several disease indications have been assessed using the OPN-KI mice covering inflammation, oncology and fibrosis showing OPN is a potential therapeutic target over a broad range of indications. Key accomplishments- Designed, screened and generated 3 mAB candidates for pivotal mouse studies in inflammation, wound healing and inflammation that (1) Block thrombin activation and (2) Neutralize activated N-terminal OPNs- Advanced one mAB to a lead compound, humanized and assessed for expression in stable pools (ATUM) and developability assessment- Developed specific mABs for biomarker and potency assays for capture and detection of OPN species in mouse, cynomolgus and human- Generated tool recombinant proteins for screening, biomarker and potency assays

University of Auckland

MSc (hons), Cell Biology

University of Otago

BSc (Hons 1st class), Microbiology

University of Cambridge

Doctor of Philosophy (PhD), Biochemistry, Biophysics and Molecular Biology